Jane Street Group LLC Grows Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

Jane Street Group LLC raised its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 26.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 161,653 shares of the medical equipment provider’s stock after buying an additional 33,417 shares during the period. Jane Street Group LLC owned about 0.16% of Accuray worth $291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ARAY. Foundry Partners LLC boosted its holdings in Accuray by 51.3% in the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares during the period. Armistice Capital LLC purchased a new position in Accuray in the second quarter valued at $910,000. Los Angeles Capital Management LLC purchased a new position in Accuray in the third quarter valued at $418,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Accuray by 489.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock valued at $500,000 after purchasing an additional 230,695 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Accuray by 143.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 384,944 shares of the medical equipment provider’s stock valued at $693,000 after purchasing an additional 226,602 shares during the period. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Up 0.5 %

Shares of NASDAQ ARAY opened at $2.14 on Friday. The company has a market capitalization of $215.21 million, a price-to-earnings ratio of -12.59 and a beta of 1.47. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The business has a 50-day moving average of $1.96 and a two-hundred day moving average of $1.90. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $2.99.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period in the previous year, the business earned ($0.03) EPS. On average, analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.